NEWTOWN, Pa., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the discontinuation of the Phase 3 ONTRAC study of intravenous (IV) rigosertib plus gemcitabine in front-line metastatic pancreatic cancer. Upon completion of a planned interim analysis, the Data Safety Monitoring Board (DSMB) determined that the combination of rigosertib and gemcitabine is unlikely to demonstrate a statistically significant improvement in overall survival compared to gemcitabine alone. There were no safety concerns raised in the DSMB review of the study.
The ONTRAC study is a randomized, multi-center, controlled Phase 3 trial of the safety and efficacy of gemcitabine alone and IV rigosertib combined with gemcitabine in patients with previously untreated metastatic pancreatic cancer. The study employed an adaptive design that allowed for an interim review of data to assess the rationale for continuing the evaluation of rigosertib plus gemcitabine in this patient population.
"We are very disappointed by these results, especially for patients with metastatic pancreatic cancer, given the lack of meaningful treatment options," said Ramesh Kumar, Ph.D., President and Chief Executive Officer of Onconova. "We would like to thank the patients and investigators for their participation in this trial."A detailed analysis of the efficacy and safety results will be conducted and presented at a future scientific meeting. Any alternative trials for this patient population may be explored upon complete analysis of this information. About Rigosertib Rigosertib is small molecule inhibitor of two important cellular signaling pathways, phosphoinositide 3-kinase, or PI3K, and polo-like kinase, or PLK, both of which are frequently overactive in cancer cells. Due to this dual effect of inhibiting the PI3K and PLK pathways, rigosertib has shown activity in a variety of cancer types including both solid tumors and hematological malignancies. Clinical trials with both intravenous and oral formulations of rigosertib have been conducted at leading institutions in the U.S. and abroad. To date, more than 1,000 patients with solid tumors and hematological diseases have received rigosertib.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV